Skip to main content

28 Result(s)

within E Boven Remove this filter Biomedicine Remove this filter Biomedicine, general Remove this filter Drug Resistance Remove this filter Epidemiology Remove this filter

Page of 2 next disabled
and

  1. No Access

    Article

    Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously

    Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a haematopoietic growth factor with a wide variety of applications in the clinic. In early phase I studies the continuous intravenous (c.i.) route o...

    AH Honkoop, K Hoekman, J Wagstaff, CJ van Groeningen… in British Journal of Cancer (1996)

  2. No Access

    Article

    Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence of the affinity on tumour uptake and efficacy of radioimmunotherapy in human ovarian cancer xenografts

    The low-affinity monoclonal antibody (MAb) chimeric 17-1A(c-17-1A) and the high-affinity MAb mouse 323/A3 (m-323/A3) were used to study the effect of the MAb affinity on the tumour uptake and efficacy of radio...

    E Kievit, HM Pinedo, HMM Schlüper, HJ Haisma, E Boven in British Journal of Cancer (1996)

  3. No Access

    Article

    The influence of the schedule and the dose of gemcitabine on the anti-tumour efficacy in experimental human cancer

    The therapeutic efficacy of gemcitabine, a new nucleoside analogue, was assessed in a variety of well-established human soft tissue sarcoma and ovarian cancer xenografts grown s.c. in nude mice. Tumour lines s...

    E Boven, H Schipper, CAM Erkelens, SA Hatty, HM Pinedo in British Journal of Cancer (1993)

  4. No Access

    Article

    The anti-tumour effects of the prodrugs N-l-leucyl-doxorubicin and vinblastine-isoleucinate in human ovarian cancer xenografts

    N-l-leucyl-doxorubicin and vinblastine-isoleucinate can be considered as relatively non-toxic prodrugs from doxorubicin and vinblastine, respectively. A comparative analysis was carried out of the anti-tumour ...

    E Boven, HR Hendriks, CAM Erkelens, HM Pinedo in British Journal of Cancer (1992)

  5. No Access

    Article

    A monoclonal antibody-β-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer

    The anti-pan carcinoma monoclonal antibody (MAb) 323/A3, linked to E. coli-derived beta-glucuronidase (GUS) was used to study the tumour-site-selective activation of the prodrug Epirubicin-glucuronide (Epi-glu...

    HJ Haisma, E Boven, M van Muijen, J de Jong, WJF van der Vijgh… in British Journal of Cancer (1992)

  6. No Access

    Article

    Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer

    Monoclonal antibody (MAb) 139H2 was previously shown to localise specifically into ovarian cancer xenografts in nude mice. MAb 139H2 was compared with MAbs OC125 and OV-TL 3, all reactive with ovarian carcinom...

    CFM Molthoff, HM Pinedo, HMM Schlüper, HW Nijman, E Boven in British Journal of Cancer (1992)

  7. No Access

    Article

    Activity of GR30921X (NSC 382057) and GR63178A (NSC D611615) in human ovarian cancer lines

    E Boven, CAM Erkelens, M Luning, HM Pinedo in British Journal of Cancer (1990)

  8. No Access

    Article

    Enhanced transplantability of human ovarian cancer lines in cyclophosphamide-pretreated nude mice

    M M Nauta, E Boven, H M Schlüper, C A Erkelens, H M Pinedo in British Journal of Cancer (1986)

Page of 2 next disabled